The same cell product could potentially be used to treat multiple solid tumors like ovarian, pancreatic and lung cancers.

Even for a newly minted Nobel laureate, downtime is hard to find. | Even for a newly minted Nobel laureate, downtime is hard ...

So far, immune cells that have been engineered to kill cancers, known as CAR T-cells, haven’t worked well against solid ...

Among 16 patients with this difficult-to-treat tumor "with few treatment options," the confirmed overall response rate (ORR) ...

The FDA has granted orphan drug status to the experimental T-cell, or Treg, therapy CK0803, being developed by Cellenkos to ...

A pan-immunotherapy biomarker predicts and reactivates CD8⁺ T cell expansion, offering new insight into treatment response.

In this tough-to-treat cancer type, more patients receiving anzu-cel saw their tumors shrink and had durable responses than what's been seen with other therapies.

In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...

Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in a nonhuman primate study, the company said.

The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the ...